ProMIS Neurosciences Inc. Common Shares (ON) closed at $3.52 on Nov 4, up 3.23%, 85.8% below its 52-week closing high. Volume of 517.0K shares was 1.54× its 20-day average (above normal).
Split-adjusted performance: -61.8% over one month, -68.0% over six months, -65.7% over one year.
Short interest was 245.8K shares at the Oct 15 settlement, up 3.0% from the prior report (3.3% of float, 7.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PMNProMIS Neurosciences Inc. Common Shares (ON) | $3.52 | +3.23% | −68.0% | — | — | — | $31.6M | |
| IXHLIncannex Healthcare Limited | $2.49 | −0.60% | −49.3% | — | — | — | $31.2M | Compare |
| RMTIRockwell Medical, Inc. (DE) | $8.05 | −0.49% | −0.6% | +10.6% | −7.5% | — | $32.4M | Compare |
| LITSLite Strategy | $1.08 | +3.85% | −9.2% | — | — | — | $32.8M | Compare |
| ACETAdicet Bio | $3.10 | −2.21% | −63.7% | — | — | — | $29.0M | Compare |
| IBOImpact BioMedical | $4.10 | +1.99% | −48.8% | −57.1% | −23300.0% | 44.4 | $35.0M | Compare |
| NNVCNanoViricides | $1.38 | −3.50% | −5.5% | — | — | — | $35.2M | Compare |
| BTMDBiote | $1.23 | +9.82% | −44.1% | −9.5% | −14.8% | 6.0 | $35.3M | Compare |
| BYSIBeyondSpring | $0.6790 | +9.34% | −56.2% | — | — | — | $27.9M | Compare |
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
